Guardian Investment Management Has $707,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Guardian Investment Management lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 2.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,900 shares of the biopharmaceutical company’s stock after selling 300 shares during the period. Guardian Investment Management’s holdings in Gilead Sciences were worth $707,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Alpha Cubed Investments LLC raised its position in Gilead Sciences by 9.8% in the 1st quarter. Alpha Cubed Investments LLC now owns 28,620 shares of the biopharmaceutical company’s stock valued at $1,701,000 after buying an additional 2,544 shares during the last quarter. Matrix Asset Advisors Inc. NY grew its stake in shares of Gilead Sciences by 10.3% in the 1st quarter. Matrix Asset Advisors Inc. NY now owns 362,989 shares of the biopharmaceutical company’s stock worth $21,580,000 after acquiring an additional 33,818 shares in the last quarter. Cullinan Associates Inc. grew its stake in shares of Gilead Sciences by 10.7% in the 1st quarter. Cullinan Associates Inc. now owns 133,543 shares of the biopharmaceutical company’s stock worth $7,939,000 after acquiring an additional 12,962 shares in the last quarter. Strs Ohio raised its holdings in shares of Gilead Sciences by 1.3% in the first quarter. Strs Ohio now owns 735,138 shares of the biopharmaceutical company’s stock valued at $43,703,000 after purchasing an additional 9,296 shares during the last quarter. Finally, CWA Asset Management Group LLC lifted its position in shares of Gilead Sciences by 70.7% during the first quarter. CWA Asset Management Group LLC now owns 7,553 shares of the biopharmaceutical company’s stock valued at $449,000 after purchasing an additional 3,127 shares in the last quarter. 80.16% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:GILD opened at $62.36 on Monday. The company has a 50-day moving average price of $61.97 and a two-hundred day moving average price of $63.67. Gilead Sciences, Inc. has a twelve month low of $57.17 and a twelve month high of $74.12. The company has a quick ratio of 1.30, a current ratio of 1.48 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $78.22 billion, a PE ratio of 17.42, a P/E/G ratio of 0.63 and a beta of 0.38.

Gilead Sciences (NASDAQ:GILDGet Rating) last released its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $2.12 EPS for the quarter, topping the consensus estimate of $1.77 by $0.35. Gilead Sciences had a net margin of 16.43% and a return on equity of 44.98%. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.28 billion. During the same period last year, the firm earned $2.08 EPS. Gilead Sciences’s revenue for the quarter was up 2.6% on a year-over-year basis. Analysts anticipate that Gilead Sciences, Inc. will post 6.59 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, June 29th. Stockholders of record on Wednesday, June 15th were given a $0.73 dividend. This represents a $2.92 annualized dividend and a dividend yield of 4.68%. The ex-dividend date was Tuesday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 81.56%.

Several research firms have commented on GILD. Piper Sandler decreased their price objective on shares of Gilead Sciences from $73.00 to $69.00 and set a “neutral” rating for the company in a research note on Monday, May 16th. Wells Fargo & Company decreased their price target on Gilead Sciences from $70.00 to $63.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 22nd. StockNews.com initiated coverage on Gilead Sciences in a research report on Thursday, March 31st. They issued a “buy” rating on the stock. Barclays decreased their target price on Gilead Sciences from $63.00 to $56.00 and set an “underweight” rating for the company in a research report on Thursday, March 10th. Finally, SVB Leerink started coverage on shares of Gilead Sciences in a report on Monday, May 23rd. They issued a “market perform” rating and a $68.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $72.07.

About Gilead Sciences (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Read More

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.